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INTRODUCTION 
 
Muscle wasting, defined as loss of muscular mass and 
contractile capacity, is both a physiological consequence of 
normal aging and a common premature aging phenotype  
 
in patients with chronic kidney disease (CKD) [1]. 
Previous observational studies showed an association 
between muscle wasting and mortality in both pre-dialysis 
CKD patients and end-stage renal disease patients on 
dialysis [2, 3]. Because effective therapies to slow muscle 
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ABSTRACT 
 
Skeletal muscle wasting represents both a common phenotype of aging and a feature of pathological conditions 
such as chronic kidney disease (CKD). Although both clinical data and genetic experiments in mice suggest that 
hyperphosphatemia accelerates muscle wasting, the underlying mechanism remains unclear. Here, we showed 
that inorganic phosphate (Pi) dose-dependently decreases myotube size, fusion index, and myogenin 
expression in mouse C2C12 skeletal muscle cells. These changes were accompanied by increases in reactive 
oxygen species (ROS) production and Nrf2 and p62 expression, and reductions in mitochondrial membrane 
potential (MMP) and Keap1 expression. Inhibition of Pi entry, cytosolic ROS production, or Nrf2 activation 
reversed the effects of high Pi on Nrf2, p62, and myogenin expression. Overexpression of Nrf2 respectively 
increased and decreased the promoter activity of p62-Luc and myogenin-Luc reporters. Analysis of nuclear 
extracts from gastrocnemius muscles from mice fed a high-Pi (2% Pi) diet showed increased Nrf2 
phosphorylation in sham-operated and 5/6 nephrectomized (CKD) mice, and both increased p62 
phosphorylation and decreased myogenin expression in CKD mice. These data suggest that high Pi suppresses 
myogenic differentiation in vitro and promotes muscle atrophy in vivo through oxidative stress-mediated 
protein degradation and both canonical (ROS-mediated) and non-canonical (p62-mediated) activation of Nrf2 
signaling. 
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wasting in such cases are lacking, further knowledge of the 
mechanisms involved in muscle wasting are required. 
 
The kidney plays a critical role in regulating serum 
phosphate (Pi) levels. In the setting of kidney 
dysfunction, hyperphosphatemia may occur as a result 
of reduced Pi excretion due to declining glomerular 
filtration rate (GFR) [4]. Evidence suggesting that Pi is 
indeed a pro-aging factor received strong support from 
recent aging research using genetically engineered 
mouse models, which revealed a potential link between 
excess Pi and muscle wasting [5]. In mice, for example, 
both fibroblast growth factor 23 (FGF23) and the renal 
transmembrane protein Klotho act as Pi-regulating 
hormones whose genetic ablation leads to 
hyperphosphatemia and premature aging phenotypes, 
including muscle atrophy. Notably, muscle atrophy and 
other premature aging phenotypes were reversed in both 
Klotho- and FGF23-knockout mice by either a low-Pi 
diet or by genetic ablation of renal sodium-dependent Pi 
transporter solute carrier family 34, member 1 (NaPi2a) 
[5–7]. The molecular mechanisms underlying high Pi-
induced muscle atrophy are not yet fully understood, 
but there is increasing evidence that oxidative stress and 
activation of the Nrf2/Keap1/p62 pathway may be 
involved. 
 
Increased oxidative stress characterizes a variety of 
disorders, including cancer, heart failure, chronic 
obstructive pulmonary disease, and kidney disease, all 
of which are associated with skeletal muscle atrophy. 
Excess production of reactive oxygen species (ROS) 
may inhibit muscle protein synthesis and promote 
protein breakdown, leading to muscle atrophy [8]. 
Accumulation of ROS under oxidative stress conditions 
is linked to canonical activation of nuclear factor 
erythroid 2-related factor 2 (Nrf2), a sensor of oxidative 
stress [9], by preventing binding to its native repressor 
Kelch-like ECH-associated protein 1 (Keap1). Keap1 is 
an adapter substrate of Cullin 3 (Cul3) ubiquitin E3 
ligase complex and represses Nrf2 activity through 
sequestration, ubiquitination, and proteasomal 
degradation under basal conditions. During oxidative 
stress, elevated ROS generation triggers oxidation of 
specific cysteine residues in Keap1. This reduces Nrf2 
ubiquitination and promotes its nuclear translocation 
and activation [10]. Moreover, recent research 
demonstrated that oxidative stress induces Nrf2 gene 
expression and transcriptional activity in C2C12 
skeletal muscle cells and in rodent skeletal muscles [11–
13]. In turn, inhibition of Nrf2 using small interfering 
RNA (siRNA) enhanced, while upregulation of Nrf2 
using sulforaphane inhibited, myogenic differentiation 
of C2C12 cells [12, 13]. Notably, high Pi concentrations 
in vitro reportedly induce oxidative stress by altering 
mitochondrial membrane potential (MMP) and 
oxidative phosphorylation in insulin-secreting cells [14, 
15] and endothelial cells [16]. These data suggest that 
oxidative stress-mediated Nrf2 activation may play a 
role in the pathogenesis of muscle wasting induced by 
high Pi. 
 
p62 is a stress-inducible, multifunctional protein. 
Accumulation of p62-enriched, polyubiquitinated 
misfolded proteins leads to inclusion body formation. In 
addition, p62 can also target ubiquitinated proteins to 
the autophagic machinery for lysosomal degradation 
[17]. Recent studies have shown that age-related 
skeletal muscle atrophy is characterized by abnormal 
p62 accumulation [18]. In mice, muscle-specific 
deletion of the autophagy-related genes Atg5 or Atg7 
results in skeletal muscle atrophy accompanied by 
accumulation of p62 [19, 20]. Furthermore, various 
stress conditions induce phosphorylation of p62 at a 
serine residue within its Keap1-interacting region 
(KIR), which markedly enhances its binding affinity for 
Keap1. As a result, phosphorylated p62 competitively 
inhibits the interaction between Nrf2 and Keap1, 
leading to non-canonical activation of Nrf2 [10]. This 
evidence suggests a possible link between p62 and 
Nrf2/Keap1 in the pathogenesis of muscle wasting. 
 
The aim of the present study was to determine the 
influence of hyperphosphatemia on both skeletal muscle 
cell differentiation in vitro and on CKD-associated 
muscle wasting in vivo. We hypothesized that 
hyperphosphatemia induces muscle wasting by 
increasing oxidative stress, p62 phosphorylation, and 
activation of Nrf2 transcriptional activity. To test this 
hypothesis, we determined the effects of high Pi on 
myogenic differentiation, generation of mitochondrial 
and cytosolic ROS, and expression of Nrf2, Keap1, p62 
and the myogenic differentiation marker myogenin in 
C2C12 skeletal muscle cells. To evaluate the effect of 
high Pi in vivo, we measured serum markers of Pi 
homeostasis, grip strength, and Nrf2, p62, and 
myogenin expression in gastrocnemius (GA) muscle 
samples from sham-operated and CKD mice fed a 
normal Pi or a high Pi diet. Our findings implicate both 
canonical and non-canonical activation of Nrf2 as 
prominent mechanisms contributing to CKD-associated 
muscle atrophy. 
 
RESULTS 
 
High Pi stimulation suppresses differentiation of 
C2C12 skeletal muscle cells 
 
Under normal differentiating conditions (2% HS), a 
time-dependent increase in the number of multinucleate 
myotubes was observed in cultured C2C12 cells (Figure 
1A). During this period, cell cycle phase distribution 
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analysis indicated a predominant G1 phase arrest and 
decreased S and G2/M phases (Figure 1B). In parallel, 
upregulation of differentiation markers, including 
myogenin, myosin heavy chain (MYH), and troponin I, 
was observed at both the mRNA and protein levels 
(Figure 1C and 1D). Meanwhile, although protein levels 
of p21 and cyclin D1 varied, levels of p21 mRNA  
were increased, while levels of cyclin D1 mRNA  
were decreased in differentiating C2C12 cells (Figure 
1C and 1D). 
 
 
 
Figure 1. Morphological characteristics of proliferating and differentiating C2C12 cells in vitro. Mouse C2C12 myoblasts were 
cultured for 3 days in growth medium (DMEM/HG plus10% FBS), followed by 4-day incubation in differentiation medium (DMEM/HG plus 2% 
HS). (A) Morphological changes in C2C12 cells during the time course of proliferation and differentiation. Representative micrographs were 
obtained using a light microscope at 40x (upper row) or 100x (lower row) magnification. The arrows indicate mature, multinucleated 
myotubes. (B) Cell cycle phase distributions during the course of C2C12 growth and myogenesis. (C) Whole-cell lysate immunoblots from 
cultured C2C12 cells assessing the expression of myogenic differentiation markers (myogenin, MYH, and troponin I) and cell cycle regulators 
(p21 and cyclin D1). β-actin was used as loading control. (D) RT-PCR analysis of myogenin, MYH, troponin I, p21 and cyclin D1 mRNA in 
cultured C2C12 cells. GAPDH was used as loading control. Data are presented as means ± SEM. 
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To model the clinical conditions observed in cases of 
acquired hyperphosphatemia, we assessed the effects of 
high Pi on myogenic differentiation. As shown in 
Figure 2A–2D, C2C12 cells exposed to 3 or 4 mM Pi 
for 24 h during the differentiation stage exhibited fewer 
nuclei per myotube, a lower fusion index (i.e. the 
number of nuclei in myotubes divided by total number 
of nuclei in both myotubes and myoblasts), and reduced 
myotube length and width. In turn, expression of 
MyoD, myogenin, and MYH was reduced at both the 
protein and mRNA levels, while decreased expression 
of Troponin I was detected at the protein but not mRNA 
level (Figure 2E and 2F). Compared to untreated 
controls, p21 protein as well as cyclin D1 protein and 
mRNA were upregulated by high Pi in differentiating 
C2C12 cells (Figure 2E and 2F). Although most C2C12 
cells remained arrested at G1 phase, high Pi treatment 
(3 or 4 mM) appeared to induce a small increase in the 
populations at S (p < 0.01) and G2/M (p < 0.05) phase 
(Figure 2G). 
 
High Pi decreases MMP and increases oxidative 
phosphorylation in differentiating C2C12 cells 
 
It was previously reported that disruption of the MMP 
mediates hyperphosphatemia-induced cell dysfunction 
[14]. To investigate whether mitochondrial dysfunction 
is involved in high Pi-mediated suppression of C2C12 
cell differentiation, we measured MMP, OCR, and 
ECAR in C2C12 cells exposed to various Pi 
concentrations. Using flow cytometry and the 
fluorescent indicator JC-1, we found that MMP was 
significantly lower in differentiating C2C12 cells 
exposed to 4 mM Pi than in untreated control cells (p < 
0.01; Figure 3A). As shown in Figure 3B–3D, C2C12 
cells differentiated under control conditions (2% HS) 
had a lower basal OCR, an indicator of mitochondrial 
respiration, and a lower basal ECAR, an indicator of 
cellular glycolysis, than proliferating cells (10% FBS). 
In contrast, the OCR/ECAR ratio in differentiated 
C2C12 cells was significantly increased upon high Pi 
exposure (p < 0.01), indicating an increase in oxidative 
phosphorylation (OXPHOS) over glycolysis (Figure 3E 
and 3F). In addition, both maximum respiration and 
spare respiratory capacity were increased by high Pi 
(Figure 3G). 
 
High Pi induces ROS generation and protein 
synthesis/degradation imbalance in differentiating 
C2C12 cells 
 
Because hyperphosphatemia reportedly promotes 
oxidative stress in cultured insulin-secreting [14] and 
endothelial cells [16], we wondered whether enhanced 
ROS production also contributes to high Pi-mediated 
suppression of skeletal muscle cell differentiation. 
Measurements of cytosolic ROS levels using the 
fluorescent indicator H2DCFDA and flow cytometry 
indicated that basal cytosolic ROS levels were higher in 
differentiating (2% HS) C2C12 cells than in 
proliferating (10% FBS) cells (Figure 4A and 4B). This 
suggested that there is a rise in endogenous ROS levels 
during in vitro differentiation of C2C12 cells. High Pi 
treatment led to further increases in cytosolic ROS 
generation, which were greater in differentiating than in 
proliferating cells (Figure 4A and 4B). Assessment of 
mitochondrial ROS levels using Mito SOX-Red staining 
revealed that high Pi (4 mM) also increased 
mitochondrial ROS generation (Figure 4C and 4D). The 
increase in cytosolic and mitochondrial ROS levels 
induced by high Pi could be neutralized with N-
acetylcysteine (NAC), a well-known ROS scavenger, 
but not by Mito-TEMPO, a mitochondrial ROS 
scavenger (Figure 4C and 4D). Since high ROS levels 
were shown to induce skeletal muscle wasting by 
attenuating protein synthesis and accelerating 
proteolysis [8], we examined by western blotting 
whether a similar effect occurs in C2C12 cells. 
Consistent with the referred study, we found that Pi 
dose-dependently increased protein degradation and 
decreased protein synthesis, as reflected by lower 
expression of phosphorylated mTOR and S6K and 
higher expression of MuRF1 and atrogin-1 (Figure 4E 
and 4F). 
 
High Pi induces canonical and non-canonical Nrf2 
activation and myogenin suppression in 
differentiated C2C12 cells 
 
Accumulation of ROS under oxidative stress conditions 
mediates canonical activation of Nrf2, a central 
regulator of cellular antioxidant responses, by 
preventing binding to Keap1, its native repressor [9, 
10]. Research has shown that siRNA-mediated 
inhibition of Nrf2 enhances myogenic differentiation in 
cultured C2C12 cells, while sulforaphane-induced Nrf2 
upregulation has the opposite effect [13]. Using western 
blotting, we observed that Nrf2 expression increased 
when C2C12 cells transitioned from the proliferative to 
the differentiative stage (Figure 5A). Moreover, 
incubating differentiated C2C12 cells with 0 to 4 mM Pi 
dose-dependently increased Nrf2 while decreasing 
Keap1 levels within cells (Figure 5B). 
 
Non-canonical Nrf2 activation can be triggered by 
Keap1 degradation mediated by the autophagy adaptor 
p62 [21, 22]. To investigate whether this mechanism is 
also involved in Nrf2 activation induced by high Pi, we 
assessed the effect of Pi on p62 expression in 
differentiating C2C12 cells. We found that p62 
expression increased gradually and significantly over 
the course of differentiation. On the other hand, 
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Figure 2. High Pi impairs C2C12 cell differentiation.  C2C12 cells were differentiated in DMEM/HG plus 2% HS for 3 days and 
treated for an additional 24 h with the indicated Pi concentrations. The cells were then collected and processed for the following 
analyses: (A) Number of nuclei per myotube (MYH staining) (B) Fusion index (C) Myotube length (D) Myotube width (E) Immunoblot 
analysis of myogenic differentiation markers (MyoD, myogenin, MYH and troponin I) and cell cycle regulators (p21 and cyclin D 1) in 
whole-cell C2C12 lysates. β-actin was used as loading control. (F) RT-PCR analysis of MyoD1, myogenin, MYH, troponin I, p21, and cyclin 
D1. GAPDH was used as loading control. (G) Cell cycle phase distributions. Data are presented as means ± SEM. *P < 0.05, **P < 0.01, 
***P < 0.001. 
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Figure 3. High Pi impairs mitochondrial function in differentiated C2C12 cells. Mitochondrial function was assayed by determining 
MMP, OCR, and ECAR in 3-day-differentiated C2C12 cells treated with the indicated concentrations of Pi for 24 h. (A) Flow cytometric analysis 
of MMP (JC-1 staining). Cells exposed to H2O2 (10 mM) for 1 h served as positive control. (B) OCR (pmol/min) and (C) ECAR (mpH/min) were 
measured in proliferating (10% FBS) and differentiated (2% HS) C2C12 cells using a Seahorse XF24 analyzer. (D) Comparison of basal OCR 
between proliferating and differentiated C2C12 cells. (E) OCR and (F) ECAR measurements in 3-day-differentiated C2C12 cells treated with 
the indicated concentrations of Pi for 24 h. (G) OCR/ECAR ratios during basal and maximal respiration in differentiated C2C12 cells treated 
with the indicated concentrations of Pi. Data are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, compared to control 
(vehicle). 
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Figure 4. High Pi induces ROS generation in differentiated C2C12 cells. (A) Analysis of cytosolic ROS levels via H2DCFDA flow 
cytometry in proliferating (10% FBS) and differentiated (2% HS) C2C12 cells treated with the indicated concentrations of Pi for 24 h. (B) Bar 
graph summarizing the data from panel A. Cells exposed to 1 mM H2O2 served as positive control. *P < 0.05, **P < 0.01 vs. 0 mM Pi. (C) 
Assessment of mitochondrial and cytosolic ROS levels via MitoSOX Red and H2DCFDA flow cytometry. Differentiated C2C12 cells were 
treated for 24 h with 4 mM Pi plus the mitochondria-targeted ROS scavenger Mito-TEMPO (10 μM) or the cytosolic ROS scavenger NAC (10 
mM). (D) Bar graph summarizing the data from (C). *P < 0.05, **P < 0.01, ***P < 0.001. (E) Representative immunoblot and (F) densitometric 
analyses of protein synthesis (mTOR and S6K) and degradation (MuRF1 and atrogin-1) markers in 3-day-differentiated C2C12 cells treated for 
24 h with the indicated concentrations of Pi. *P < 0.05, **P < 0.01, ***P < 0.001 vs. 0 mM Pi.
 #
P > 0.05. Data are presented as means ± SEM. 
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phosphorylated p62 levels were significantly decreased 
in differentiating cells (Figure 5A). However, a dose-
dependent increase in p62 protein expression occurred 
upon Pi treatment, with a maximal stimulatory effect on 
p62 phosphorylation at Ser349 occurring at 3 mM Pi 
(Figure 5B). Following cellular fractionation, additional 
immunoblot assays showed that exposure to high Pi led 
to increased Nrf2 and p62, and reduced myogenin 
protein levels, both in the nucleus and the cytosol 
(Figure 5C). These findings were verified by 
immunofluorescence analyses, which confirmed altered 
expression of Nrf2, p62, and myogenin in C2C12 cells 
exposed to high Pi (Figure 5D).  
 
Blockade of Pi transport, ROS generation, and Nrf2 
activation attenuates high Pi-induced Nrf2 activation 
and myogenin suppression in differentiated C2C12 
cells 
 
To further confirm the impact of high Pi-induced ROS 
production and Nrf2 activation on skeletal muscle cell 
differentiation, we treated differentiated C2C12 cells 
with high Pi combined with a Pi transporter inhibitor, a 
ROS scavenger, or Nrf2 modulators and determined 
their effects on the expression of Nrf2, p62, and 
myogenin. Consistent with our previous observations, 
the Pi transporter inhibitor phosphonoformic acid (PFA) 
dose-dependently inhibited the increase in Nrf2 and p62 
expression and the reduction in myogenin expression 
induced by high Pi (Figure 6A). To evaluate whether 
enhanced ROS generation under high Pi conditions 
mediates the observed changes in Nrf2, p62, and 
myogenin expression, we conducted western blot assays 
after co-application of two antioxidants, Mito-TEMPO 
and NAC. We found that NAC, but not Mito-TEMPO, 
attenuated Nrf2 and p62 expression, as well as 
myogenin suppression, in cells treated with high Pi 
(Figure 6B). Neither an Nrf2 activator (oltipraz), nor 
two Nrf2 inhibitors (trigonelline and clobetasol 
propionate [23]), significantly affected Nrf2, p62, nor 
myogenin expression in differentiated C2C12 cells 
treated with or without high Pi (Figure 6C). In contrast, 
exposure to either metformin or phenformin 
significantly diminished the stimulatory effect of high 
Pi on Nrf2 and p62 expression, as well as its inhibitory 
effect on myogenin expression (Figure 6C). 
 
Overexpression of Nrf2 increases p62 and decreases 
myogenin promoter activity 
 
Nrf2 induces the transcription of various antioxidant 
genes by binding to antioxidant response elements 
(ARE) in their promoters. The ARE consensus sequence 
is present in the promoter regions of the mouse p62 and 
myogenin genes, and previous studies have shown that 
modulation of Nrf2 expression influences p62 and 
myogenin promoter activity in C2C12 and HEK 293 
cells [13, 24, 25]. To investigate whether Nrf2 
transactivates p62 and myogenin gene expression 
following high Pi treatment, we first made two 
luciferase reporter constructs driven by ARE sequences 
in the mouse p62 and myogenin promoters (Figure 7A 
and 7B). The p62-Luc and the myogenin-Luc reporter 
plasmids were alternatively transfected into 
undifferentiated C2C12 cells, which were then treated 
for 24 h with 0-4 mM Pi. As shown in Figure 7C and 
7D, a decrease in p62 promoter activity and an increase 
in myogenin promoter activity was observed in a 
concentration-dependent manner. To further verify that 
p62 and myogenin are Nrf2 target genes in skeletal 
muscle cells, we co-transfected a Nrf2 expression vector 
with p62-Luc or myogenin-Luc reporter plasmids into 
undifferentiated C2C12 cells. Results indicated that 
overexpression of Nrf2 dose-dependently increased p62 
promoter activity while repressing the activity of the 
myogenin promoter (Figure 7E and 7F). Meanwhile, 
site-directed mutations in the ARE of the p62 promoter, 
but not in the ARE of the myogenin promoter, 
significantly diminished Nrf2-induced luciferase 
expression (Figure 7E and 7F). These data indicate the 
functionality of the ARE in the p62, but not the 
myogenin, promoter. In addition, an assessment of the 
effects of Nrf2 overexpression and high Pi on the Nrf2 
promoter reporter (Nrf2(ARE)-LUC), used as positive 
control, indicated that the stimulation exerted by Nrf2 
on both p62 and myogenin promoter activity may be 
only marginally affected by Pi levels (Figure 7G). 
Indicating successful nuclear delivery of Nrf2 following 
transfection of pEGFP-mouse(m)Nrf2 plasmid, a strong 
green fluorescent signal, unaffected by high Pi 
treatment, was detected in cell nuclei (Figure 7H).  
 
p62-mediated proteasomal degradation and protein 
aggregation does not participate in high Pi-induced 
downregulation of myogenin expression 
 
Actinomycin D (Act D) and cycloheximide (CHX) 
inhibit de novo RNA and protein synthesis by binding 
to the transcription initiation complex and by interfering 
with the translocation step of protein synthesis, 
respectively [26]. As shown in Figure 8A, treatment of 
differentiated C2C12 cells with Act D or CHX 
significantly suppressed myogenin expression 
independently of Pi, which suggests that in these cells 
the myogenin mRNA and its encoded protein are both 
labile. Furthermore, the expression of both Nrf2 and 
p62 was unaffected and stimulated, respectively, by pre-
treatment (2 h) with Act D and CHX (Figure 8A). In 
turn, pre-treating differentiated C2C12 cells with the 
proteasome inhibitor MG132 did not alter the inhibitory 
effect of high Pi on myogenin expression, but slightly 
reduced Nrf2 and p62 expression (Figure 8A). To 
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Figure 5. High Pi activates signaling pathways associated with oxidative stress in differentiated C2C12 cells. (A) Representative 
Nrf2 and p62 immunoblots from whole-cell lysates prepared from proliferating and differentiated C2C12 cells. β-actin was used as loading 
control. (B) Representative immunoblots (upper panel) and densitometric analysis (lower panel) of Nrf2, Keap1, and p62 expression in whole-
cell lysates from 3-day-differentiated C2C12 cells treated for 24 h with the indicated Pi concentrations. Data are presented as means ± SEM. 
*P < 0.05 vs. 0 mM Pi. (C) Representative immunoblots of cytosolic and nuclear Nrf2, p62, and myogenin expression in 3-day-differentiated 
C2C12 cells treated for 24 h with the indicated Pi concentrations. (D) Representative confocal micrographs of Nrf2 (green), p62 (green) and 
myogenin (red) immunofluorescence in differentiated C2C12 cells treated with the indicated Pi concentrations. Nuclei were stained using 
DAPI (blue). The boxed areas within Nrf2 staining images are reproduced at higher magnification in the panels immediately below. Arrows 
highlight positive nuclear Nrf2 expression.  
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Figure 6. Inhibition of Pi transport, ROS production, or Nrf2 activity counteracts high Pi-induced changes in Nrf2, p62, and 
myogenin expression in differentiated C2C12 cells. (A, B) Representative immunoblots of p62, Nrf2, and myogenin expression in 
whole-cell lysates of 3-day-differentiated C2C12 cells treated for 24 h with (A) PFA or (B) 10 μM Mito-TEMPO or 10 mM NAC. (C) Immunoblot 
analysis of Nrf2, p62, and myogenin expression in whole-cell lysates of 3-day-differentiated C2C12 cells treated for 24 h with 4 mM Pi and 
various Nrf2 modulators. β-actin was used as loading control. Data are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. 
corresponding control Pi (-) plus vehicle, Mito-TEMPO, or NAC. 
#
P > 0.05.  
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further clarify whether the observed reduction in 
myogenin expression is attributable to increased p62-
mediated formation of protein aggregates, we isolated 
protein aggregates from differentiated C2C12 cells 
treated with 0 to 5 mM Pi and determined their 
myogenin content. Western blotting results revealed 
that Pi treatment induced concentration-dependent 
increases in Nrf2 and p62 expression, and a decrease in 
myogenin levels, within protein aggregates from both 
differentiated C2C12 cell lysates and the corresponding 
 
 
 
Figure 7. Nrf2 overexpression increases p62 and decreases myogenin promoter activity. Schematic diagram of predicted AREs 
(dark modules) and corresponding mutant ARE sequences within the mouse p62 (A) and myogenin (B) promoter regions, as determined using 
Genomatix-MatInspector software. (C, D) Luciferase reporter assay results. C2C12 cells were transiently transfected with a mSQSTM1/p62 (-
2550/+63)-LUC reporter (C) or a myogenin (-2715/+52)-LUC reporter (D) and then treated for 24 h with the indicated Pi concentrations. (E, F) 
Luciferase activity measurements in C2C12 cells transiently co-transfected (24 h) with an Nrf2 expression plasmid plus a mSQSTM1/p62 (-
2550/+63)-LUC (E) or a myogenin (-2715/+52)-LUC (F) reporter plasmid containing wild-type or mutant AREs. (G) Luciferase activity 
measurements in C2C12 cells transiently co-transfected with Nrf2(ARE)-LUC, mSQSTM1/p62 (-2550/+63)-LUC, or myogenin (-2715/+52)-LUC 
reporter plasmids plus an Nrf2 expression plasmid and treated for 24 h with the indicated Pi concentrations. (H) Representative fluorescence 
micrographs of C2C12 cells transfected with 0.5 μg of pEGFP.mNrf2 or pEGFP plasmid DNA in the presence or absence of 4 mM Pi. Data are 
presented as means ± SEM. PH, phase contrast. 
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supernatants (Figure 8B). In time-course experiments in 
differentiated C2C12 cells (Figure 8C), myogenin 
protein was degraded within 2 h after CHX treatment, 
while MG132 failed to suppress myogenin degradation 
induced by high Pi treatment. Meanwhile, the 
stimulatory effect of high Pi on Nrf2 and p62 protein 
expression was not affected by MG132 treatment, 
whereas CHX exposure stabilized Nrf2 and p62 protein 
levels regardless of the Pi concentration present in the 
culture medium. 
 
High Pi diet affects muscle Nrf2, p62, and myogenin 
expression in both sham and CKD mice  
 
Muscle atrophy is a common issue in patients with CKD 
[1]. To investigate whether Pi availability impacts 
skeletal muscle properties in CKD, we fed sham-operated 
and 5/6 nephrectomized (CKD) mice a high (2.0%) Pi 
(HP) diet for 5 months and then assessed blood 
chemistry, muscle weight, hindlimb grip strength, and 
Nrf2, p62, and myogenin expression in the gastrocnemius 
 
\ 
 
Figure 8. Inhibition of RNA transcription, protein synthesis, or proteasome formation does not reverse high Pi-induced 
myogenin downregulation. (A) Representative whole-cell lysate immunoblots for Nrf2, p62, myogenin, and LC3B. Differentiated C2C12 
cells were pretreated for 2 h with Act D (10 nM), CHX (5 μg/ml), or MG-132 (0.1 μM) and then exposed for 24 h to the indicated Pi 
concentrations. (B) Immunoblot analysis of Nrf2, p62, myogenin, LC3B, MYH, and MLC-2v content in protein aggregates from differentiated 
C2C12 cells treated for 24 h with the indicated Pi concentrations. (C) Immunoblot analysis of Nrf2, p62 and myogenin expression in whole cell 
lysates from differentiated C2C12 cells treated for the indicated times with CHX or MG-132, with or without 4 mM Pi. 
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(GA) muscle. Compared to sham-operated mice fed a 
normal Pi (sham/NP) diet, sham-operated mice fed a HP 
(sham/HP) diet exhibited significantly higher iPTH and 
FGF23 levels. In CKD/NP mice, the serum BUN, Cr, 
Ca
2+
 and iPTH levels were significantly higher than those 
measured in sham/NP mice. The serum Pi levels in 
CKD/NP mice (3.01 ± 0.20 mmol/L) were similar to 
those in sham/HP mice (2.94 ± 0.07 mmol/L) but, 
although raised in comparison to that of levels in 
sham/NP mice (2.75 ± 0.10 mmol/L) this difference did 
not reach statistical significance. CKD/NP mice also 
exhibited lower body weight (BW), lower GA muscle 
weight, and a trend toward reduced grip strength 
compared to sham/NP mice. Feeding CKD mice a HP 
diet further increased serum Pi, iPTH, and FGF23 levels, 
but did not affect BW, GA muscle weight, or grip 
strength (Table 1). As shown in Figure 9A–9D, 
cytoplasmic levels of phosphorylated Nrf2 (Ser40) in GA 
muscle samples were similar among groups. On the other 
hand, nuclear levels of phosphorylated Nrf2 were 
upregulated in CKD/NP, sham/HP, and CKD/HP mice, 
with the greatest increase observed in the CKD/HP 
group. In turn, compared to sham/NP mice, 
phosphorylated p62 (Ser349) levels were significantly 
decreased and increased, respectively, in cytosolic and 
nuclear fractions of GA samples from CKD/HP mice. In 
line with these immunoblotting results, 
immunohistochemical assays revealed higher nuclear 
expression of phosphorylated Nrf2 in GA muscle 
sections from CKD/NP and sham/HP mice, compared 
with sham/NP mice. This expression pattern was, in turn, 
more pronounced in CKD/HP mice (Figure 9E and 9F). 
Meanwhile, administration of the HP diet decreased 
cytoplasmic myogenin expression in GA muscles of 
sham-operated mice, and suppressed both cytoplasmic 
and nuclear myogenin expression in CKD mice (Figure 
10A and 10B). 
 
DISCUSSION 
 
Muscle atrophy is both a physiological consequence of 
aging (i.e. sarcopenia) and a pathological feature of 
CKD and other diseases. Although a link between 
hyperphosphatemia and skeletal muscle atrophy has 
been suggested by some studies, the mechanisms 
involved are not fully understood. The present study 
demonstrates that exposing C2C12 skeletal muscle cells 
to high Pi leads to changes consistent with muscle 
wasting, namely reduced myotube size, increased ROS 
generation, decreased protein synthesis, and accelerated 
protein degradation. High Pi also suppressed normal in 
vitro differentiation of C2C12 cells, evidenced by fewer 
nuclei per myotube, a lower fusion index, and reduced 
expression of the differentiation markers myogenin, 
MyoD, MYH, and troponin I. This suppression was 
accompanied by an increase in ROS generation and 
mitochondrial oxygen consumption, upregulation of 
MuRF1, atrogin-1, Nrf2, and p62 protein expression, 
and downregulation of mTOR, S6K, and Keap1 protein 
expression. Pharmacological inhibition of Pi influx, 
scavenging cytosolic ROS, and inhibition of Nrf2 
activity diminished both the inhibitory effect of high Pi 
on myogenin expression and the stimulatory effect of 
Nrf2 on p62 expression. Suggesting a key regulatory 
role of Nrf2 in the suppression of C2C12 cell 
differentiation observed under high Pi conditions, the 
activity of the myogenin and p62 gene promoters was 
decreased and increased, respectively, by Nrf2 
overexpression. In turn, administration of a high Pi diet 
led to higher serum iPTH and FGF23 levels and 
increased Nrf2/p62 expression and reduced myogenin 
expression in GA muscles, without affecting body 
weight, GA muscle weight, or grip strength in both sham-
operated and CKD mice. These data suggest that high Pi 
suppresses skeletal muscle cell differentiation and induces 
muscle atrophy through induction of oxidative stress and 
activation of Nrf2/p62 signaling. A schematic summary of 
our findings is shown in Figure 10C. 
 
Maintaining adequate serum Pi levels is essential for 
normal skeletal muscle function. A recent study using in 
vivo saturation transfer 
31
P-magnetic resonance 
spectroscopy demonstrated that rates of muscle ATP 
synthetic flux (VATP) were decreased in mice with diet-
induced or genetically induced (NaPi2a
−/−
) 
hypophosphatemia and were restored after normalization 
of serum Pi levels through oral Pi repletion [27]. Similar 
findings were obtained in a patient carrying a SLC34A3 
mutation who presented with chronic hypophosphatemia 
[27]. On the other hand, several in vivo and in vitro 
studies have also suggested a correlation between 
hyperphosphatemia and skeletal muscle atrophy. For 
example, Ohnishi et al. recently reported that genetic 
ablation of the Pi-regulating hormones Klotho and 
FGF23 in mice leads to hyperphosphatemia and muscle 
atrophy that can be reversed by a low-Pi diet or genetic 
ablation of SLC34A1 [6]. In addition, exposing rat L6 
myotubes to high- Pi medium reportedly leads to a 
reduction in cell diameter [28]. Consistent with those 
earlier observations, we found that exposure of 
differentiated C2C12 cells to a high-Pi medium decreases 
myotube size, the number of nuclei per myotube, and the 
fusion index. High Pi treatment also reduced MyoD, 
myogenin, MYH, and troponin I expression, and caused a 
reduction in myogenin levels that was reversed by Pi 
transporter blockade using PFA. Further supporting the 
idea that high Pi suppresses myogenic differentiation and 
induces muscle wasting, a high Pi diet induced a 
significant reduction of myogenin expression in 
cytoplasmic fractions of sham-operated GA muscles and 
in both nuclear and cytoplasmic fractions of GA muscle 
samples from CKD mice. 
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Table 1. Serum biochemistry and gastrocnemius muscle weight and grip strength in WT and CKD mice fed a NP or HP 
diet. 
 Sham/NP CKD/NP  Sham/HP CKD/HP 
BUN (mg/dL) 24.16 ± 2.19 64.66 ± 4.97
a,b
 21.00 ± 1.23 38.50 ± 2.29
a,b,c
 
Cr (mg/dL) 0.21 ± 0.01 0.45 ± 0.04
ab
 0.25 ± 0.02 0.33 ± 0.02
a,b,c
 
Ca
2+
 (mmol/L) 2.20 ± 0.03 2.48 ± 0.03
a,b
 2.30 ± 0.02
a
 2.27 ± 0.02
c
 
Pi (mmol/L) 2.75 ± 0.10 3.01 ± 0.20 2.94 ± 0.07 3.48 ± 0.19
a,b,c
 
iPTH (pg/ml) 328.37 ± 30.61 861.27 ± 35.70
a,b
 1039.49 ± 83.83
a
 2347.08 ± 60.47
a,b,c
 
FGF23 (pg/ml) 293.05 ± 13.13 559.86 ± 78.07
b
 927.63 ± 200.53
a
 2543.12 ± 111.36
a,b,c
 
BW (g) 34.15 ± 0.62 28.60 ± 0.42
a,b
 34.50 ± 1.02 26.51 ± 1.18
a,b
 
GA (mg) 170.11 ± 2.28 163.59 ± 3.97
a
 173.53 ± 2.82  153.90 ± 5.42
a,b
 
GS (N) 0.75 ± 0.02 0.67 ± 0.03 0.71 ± 0.04 0.61 ± 0.02
a,b
 
WT, wild-type; CKD, chronic kidney disease; NP, normal 0.6 % phosphate diet; HP, high 2% phosphate diet; BUN, blood urea 
nitrogen; Cr, creatinine; Ca
2+
, calcium; Pi, phosphate; iPTH, intact parathyroid hormone; FGF23, fibroblast growth factor 23; 
BW, body weight; GA, gastrocnemius muscle; GS, grip strength. Data are presented as means ± SEM. N = 6 samples per group. 
a
P < 0.05 versus sham-operated mice on the NP diet; 
b
P < 0.05 versus sham-operated mice on the HP diet; 
c
P < 0.05 versus 
CKD mice on the NP diet. 
 
Excess ROS production has been shown to contribute to 
the pathogenesis of skeletal muscle wasting by 
disturbing the balance between protein synthesis and 
degradation [8]. In the present study, we observed that 
incubating differentiated C2C12 cells in a high Pi 
medium increased cytosolic and mitochondrial ROS 
levels. ROS elevation was accompanied by decreases in 
mTOR and S6K1 and increases in atrogin1 and MuRF1 
expression, which suggests that ROS-mediated 
decreases in protein synthesis and increased proteolysis 
may contribute to muscle atrophy associated with high 
Pi. Both the increase in intracellular ROS generation, as 
well as reduction in myogenin expression observed in 
high Pi-treated, differentiated C2C12 cells were 
reversed by the ROS scavenger NAC, which was 
previously shown to reduce muscle fatigue and improve 
muscle performance during exercise programs [29–31]. 
Furthermore, as in insulin-secreting cells [14], high Pi 
disrupted MMP and increased OXPHOS in 
differentiated C2C12 cells, indicating that high Pi-
mediated mitochondrial dysfunction may be an 
important source of ROS generation. 
 
Under oxidative stress conditions Keap1-mediated Nrf2 
ubiquitination is impeded, allowing Nrf2 to translocate 
into the nucleus and to initiate the transcription of genes 
containing a cis-acting ARE in their promoters [10]. 
Our studies indicate that high Pi, likely acting through 
oxidative stress, induces canonical activation of the 
Nrf2 pathway in C2C12 skeletal muscle cells in vitro. 
Overexpression of Nrf2 suppressed myogenin promoter 
activity, while treatment with the Nrf2 inhibitors 
metformin and phenformin attenuated the suppressive 
effect of high Pi on myogenin protein expression. In 
line with these observations, increases in Nrf2 activity 
induced by methysticin or sulforaphane reportedly 
suppress myogenin promoter activity in satellite cells 
and myogenin expression in C2C12 cells [13, 24]. 
Conversely, inhibition of Nrf2 using siRNA stimulates 
myogenic differentiation in C2C12 cells [13]. 
Modulation of Nrf2 activity also influences muscle 
regeneration in a murine model of hind limb ischemia–
reperfusion injury [24] and disrupts the contractile and 
metabolic properties of skeletal muscle in 
streptozotocin-induced diabetic mice [13]. In addition, 
recent studies have shown that Nrf2 may be activated 
through a non-canonical, p62-mediated pathway [10, 
22, 32]. In that regard, we observed that high Pi 
stimulated p62 expression, Nrf2 expression and nuclear 
translocation, and decreased Keap1 levels in 
differentiated C2C12 cells. This suggests that p62 
upregulation may contribute to non-canonical activation 
of Nrf2 under high Pi conditions. Moreover, our finding 
that p62 promoter activity was stimulated by 
overexpression of Nrf2, while mutation of the 
corresponding ARE sequence abolished promoter 
activation suggests that high Pi induces a positive 
feedback loop between p62 and Nrf2 in C2C12 cells. 
 
p62 modulates protein expression by targeting 
ubiquitinated proteins to the 26S proteasome and by 
shuttling misfolded proteins to the aggresome [17, 32, 
33]. Since the proteasome inhibitor MG132 did not 
prevent the high Pi-mediated decrease in myogenin 
expression, and the insoluble protein pellets extracted 
from high Pi-treated C2C12 cells were not enriched in 
myogenin, it appears that neither p62-mediated 
proteasomal degradation nor aggresome formation is 
involved in the downregulation of myogenin expression 
induced by high Pi. On the other hand, CHX increased 
Nrf2 and p62 protein stability and further suppressed 
myogenin expression in high Pi-treated, differentiated 
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C2C12 cells. These findings suggest that protein 
degradation modulates the stimulatory effect of high Pi 
on Nrf2 and p62 protein expression in skeletal muscle 
cells. 
 
Muscle wasting is a major clinical issue in CKD 
patients, where preservation of adequate muscle mass 
and function are critical concerns [1, 34]. The 
accumulation of uremic toxins caused by decreased 
renal excretion is responsible for the dysfunction of 
multiple organs during the course of progressive CKD 
[35]. Recent studies demonstrated that indoxyl sulfate, a 
protein-bound uremic toxin, negatively affects skeletal 
muscle cells by enhancing ROS production [36, 37] and 
 
 
 
Figure 9. High-Pi diet alters Nrf2 and p62 expression in GA muscle from sham-operated and CKD mice. Eight-week-old mice 
underwent either a sham operation or 5/6 nephrectomy (CKD), after which they were fed a normal Pi (NP) or high-Pi (HP) diet for 20 weeks. 
Cytosolic (A and C) and nuclear (B and D) fractions were extracted from GA muscle samples and probed for Nrf2 and p-Nrf2 (A and B) and for 
p62 and p-p62 (C and D). Levels of these proteins were quantified by computer-assisted densitometric analysis. (E) Representative images of 
p-Nrf2 immunohistochemistry in GA muscle sections. (F) Semiquantitative IHC scoring from images like those shown in (E). Data are 
presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. 
 
www.aging-us.com 21461 AGING 
inducing mitochondrial dysfunction [38]. Emerging 
evidence suggests that excess Pi should also be 
considered an uremic toxin, as it can induce various 
adverse effects, such as vascular calcification, 
endothelial dysfunction, and impaired bone 
mineralization, that accelerate aging and contribute to 
the progression of CKD [15, 39, 40]. Although we 
demonstrated that high Pi exerts a detrimental effect on 
cultured skeletal muscle cells, our in vivo findings did 
not completely recapitulate what we observed in vitro. 
Feeding 10-week-old sham-operated and CKD mice 
with an HP diet for 20 weeks had no obvious effects on 
BW, GA muscle weight, and grip strength, but 
significantly increased serum iPTH, a known muscle-
wasting factor [41] compared to their NP diet-fed 
counterparts. Furthermore, feeding the HP diet increased 
nuclear levels of phosphorylated Nrf2 in GA muscles 
from sham-operated and CKD mice, and increased 
nuclear levels of phosphorylated p62, while decreasing 
nuclear myogenin levels, in GA muscles from CKD mice. 
These findings support the notion that systemic 
hyperphosphatemia triggers pathological signaling via  
the p62/Nrf2 axis, which may contribute to the 
pathogenesis of muscle atrophy during CKD progression. 
 
 
 
Figure 10. High-Pi diet alters myogenin expression in GA muscle from sham-operated and CKD mice. Representative myogenin 
immunoblots from cytosolic (A) and nuclear (B) GA muscle fractions. Levels of these proteins were quantified by computer-assisted 
densitometric analysis. Data are presented as means ± SEM. *P < 0.05, **P < 0.01. (C) Schematic illustration of the molecular mechanism by 
which high Pi represses myogenic differentiation and promotes muscle atrophy. GA, gastrocnemius muscle; PFA, phosphonoformic acid; 
MMP, mitochondrial membrane potential; ROS, reactive oxygen species; ub-Nrf2, ubiquitinated Nrf2; ARE, antioxidant response element; Ox-
Keap1, oxidized Keap1; p-p62, phosphorylated p62. 
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Notably, a recent animal study showed that feeding 20- to 
24-week-old WT mice a HP diet for 12 weeks induced 
exercise intolerance and altered fatty acid metabolism in 
skeletal muscles [42]. Thus, we speculate that more 
definite symptoms of hyperphosphatemia-induced muscle 
wasting will be observed in older HP diet-fed mice. 
Indeed, a cross-sectional study analyzing data from the 
US National Health and Nutrition Examination Survey 
reported that higher Pi quartiles correlated with lower 
muscle strength in people older than 65 years and 
predicted a greater risk for dynapenia [43]. These data 
suggest that age might be a crucial factor modulating the 
effects of hyperphosphatemia on skeletal muscle function. 
Further studies are required to determine whether 
counterbalancing mechanisms are activated to mitigate the 
detrimental effects of high Pi on skeletal muscle function. 
 
In summary, our study suggests that high Pi suppresses 
myogenic differentiation in vitro and promotes skeletal 
muscle atrophy in vivo, especially in diseases associated 
with muscle wasting such as CKD. These effects entail 
enhanced Nrf2 transcriptional activity through both 
canonical (via ROS) and non-canonical (via p62) 
pathways. Keeping serum Pi levels within a normal 
range may help prevent skeletal muscle dysfunction 
both during aging and in muscle-wasting conditions, 
while inhibition of Pi entry into cells, cytosolic ROS 
production, or Nrf2 activation may ameliorate the 
negative effects of high Pi on skeletal muscle cells.  
 
MATERIALS AND METHODS 
 
C2C12 myotube culture and Pi treatments 
 
Mouse C2C12 myoblasts seeded into 6-well plates at a 
density of 2x10
5
 cells/well were first cultured for 3 days 
in DMEM/HG [Dulbecco's modified Eagle medium/ 
high glucose (4500 mg/L)] supplemented with 10% fetal 
bovine serum (FBS, Gibco) at 37°C and 5% CO2. They 
were then cultured for an additional 4 days in 
differentiation medium consisting of DMEM/HG 
supplemented with 2% adult horse serum (HS, Gibco). 
During this period the spindle-shaped C2C12 myoblast 
cells differentiated and fused, gradually forming 
multinucleate myotubes. The myotubes thus formed 
were then incubated for 24 h in sodium phosphate buffer 
(1M Na2HPO4/NaH2PO4, pH 7.4) titrated to achieve 
final Pi concentrations of 0, 0.5, 1, 2, 3, or 4 mM. 
Thereafter, the myotubes were harvested or lysed for 
downstream analyses. A minimum of three independent 
experiments were performed for each condition. 
 
Cell cycle, MMP, and ROS generation assays  
 
Cell cycle phase distributions were determined by 
measuring cellular DNA content using fluorescence-
activated cell sorting (FACS). Cells were harvested and 
fixed in 70% ice-cold ethanol and kept at 20°C 
overnight. Before analysis, the cells were washed twice 
with ice-cold PBS and stained with propidium iodide 
(PI; 5 μg/ml in PBS, 1.80.5% Triton X-100, and 0.5 
μg/ml RNase A) for 30 min at room temperature in the 
dark. Samples were analyzed using a FACS Calibur 
flow cytometer (BD Biosciences, CA, USA). Data were 
analyzed using Cell Quest Pro software (BD 
Biosciences).  
 
MMP was measured using a BD™ MitoScreen Flow 
Cytometry Mitochondrial Membrane Potential 
Detection Kit (BD Biosciences) according to the 
manufacturer’s instructions. In brief, C2C12 cells were 
seeded onto 6-well plates and cultured to a density of 
1.8x10
5
 cells/ml. After exposure to different Pi 
concentrations for 24 h, the cells were stained with JC-1 
staining reagent (5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimi-dazolyl carbo-cyanine iodide) for 15 
min at 37°C in a CO2 incubator. The cells were then 
washed, and JC-1 fluorescence was measured using a 
flow cytometer. The excitation wavelength was 488 nm, 
and the emission wavelengths were 530 nm (FL1-H 
channel) for monomers and 580 nm (FL2-H channel) 
for aggregates. Cytosolic and mitochondrial ROS  
levels in Pi-treated C2C12 myotubes were measured 
using the fluorescent indicator H2DCFDA (2’,7’-
dichlorodihydrofluorescein diacetate) and MitoSOX™ 
Red assay, respectively. Myotubes treated for 24 h with 
the indicated concentrations of Pi were stained with 10 
μM H2DCFDA or 5 μM MitoSOX™ Red at 37°C. 
After incubation for 30 min, ROS levels were assessed 
by flow cytometry at excitation/ emission wavelengths 
of 488/525 nm.  
 
Measurement of oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR)  
 
Cellular OCR and ECAR were measured using XF24 
bioenergetic assays according to the manufacturer’s 
instructions (Seahorse Biosciences, Billerica, MA, 
USA). Briefly, C2C12 cells were suspended in DMEM 
containing 10% FBS and then seeded onto an XF24 
microplate. For C2C12 myotube differentiation, growth 
medium was changed to DMEM/HG with 2% HS, and 
the cells were incubated for an additional 3 days, after 
which the assays were initiated by removing the 
exhausted medium and replacing it with sodium 
bicarbonate-free DMEM (pH 7.4) containing 2% FBS 
and 2% HS. OCR and ECAR were detected at steady 
state. Oligomycin (1 μM), carbonyl cyanide 4-
[trifluoromethoxy] phenylhydrazone (FCCP; 0.5 μM), 
and rotenone/antimycin A (Rot-Ant A; 0.5 μM) were 
added sequentially to the wells to determine the 
maximal and non-mitochondrial respiration rates. 
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Whole-cell, cytoplasmic, and nuclear extract 
preparations 
 
C2C12 cells (2x10
5
 cells/well) were grown to 
confluence in 100 mm culture dishes and collected by 
Trypsin–EDTA. To prepare whole-cell extracts, C2C12 
cells and gastrocnemius (GA) muscle samples were 
lysed in lysis buffer [50 mM HEPES (pH 7.6), 150 mM 
NaCl, 0.5% Triton X-100, 10% glycerol, and 0.1% 
dodecyl sulfate] at 4°C and centrifuged for 15 min at 
14,000×g, 4°C. Cytoplasmic and nuclear extracts from 
C2C12 cells were prepared with a ProteoExtract® 
Subcellular Proteome Extraction Kit (Merck Millipore, 
MA, USA). Cytoplasmic and nuclear extracts from GA 
samples were prepared with a Subcellular Protein 
Fractionation Kit for Tissues (Thermo Fisher Scientific, 
CA, USA). 
 
Western blotting 
 
C2C12 cells and GA samples were lysed in lysis buffer 
[50 mM HEPES (pH 7.6), 150 mM NaCl, 0.5% Triton 
X-100, 10% glycerol, and 0.1% dodecyl sulfate] for 30 
min at 4°C. The resultant protein extracts were separated 
by SDS-PAGE and electrotransferred onto PVDF 
membranes (Immobilon-P; Millipore, MA, USA). The 
membranes were then incubated with primary antibodies 
against proteins of interest (Supplementary Table 1). 
Following addition of HRP-conjugated secondary 
antibodies, immunoreactive bands were detected using 
enhanced chemiluminescence (Pierce, Rockford, IL, 
USA). To analyze protein expression in cellular protein 
aggregates, total protein was extracted into RIPA buffer, 
centrifuged, and the pellet collected and eluted with 8 M 
urea. To normalize protein expression, beta-actin (β-
actin), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), and HuR were used as an internal controls for 
whole-cell lysates, cytoplasmic extracts, and nuclear 
extracts, respectively. Pixel density scanning using 
Molecular Analyst software (Bio-Rad, Hercules, CA, 
USA) was applied for quantification of immunopositive 
bands. 
 
Reverse transcription-polymerase chain reaction 
(RT-PCR) 
 
Total RNA was isolated using TRIsure (Bioline, London, 
UK) reagent according to the manufacturer’s instructions. 
For 1st-strand cDNA synthesis, 1 µg of total RNA was 
reverse transcribed using 200 U of M-MLV reverse 
transcriptase (Epicentre Biotechnologies, WI, USA) for 
60 min at 37°C. Specific primers (Supplementary Table 
2), dNTPs, and Taq DNA polymerase were added for 
subsequent PCR reactions on a Veriti Thermal Cycler 
(Applied Biosystems, MA, USA). GAPDH was used as 
an internal control to normalize gene expression. 
Immunohistochemistry 
 
GA muscles were collected and fixed in 4% 
paraformaldehyde for 24 h. The samples were then 
embedded in paraffin and transversely sectioned  
(4 μm) from the mid-belly of the muscles. For 
immunohistochemical staining, deparaffinized tissue 
sections were incubated with primary antibody against 
phosphorylated Nrf2 (Abcam, Cambridge, MA, USA) at 
4°C overnight. The sections were then washed in PBST 
and incubated with HRP Labeled Polymer (Dako, 
Glostrup, Denmark) for 1 h. Antigen-antibody complexes 
were visualized using DAB chromogen (Dako) followed 
by hematoxylin counterstain. Semiquantitative analysis 
of tissue immunoreactivity was done by two pathologists 
using an immunohistochemical rating score (IRS). Five 
randomly selected fields per tissue section per mouse 
were evaluated using high power (×400) microscopy. In 
brief, the intensity was rated as 0, no staining; 1, weak 
staining; 2, moderate staining; and 3, strong staining. The 
quantity of positively stained cells for each section was 
defined as 0, no cells; 1, <10%; 2, 10% to 50%; 3, 51% 
to 80%; and 4, >80%. The IRS was obtained by 
multiplying the percentage of positive cells by the 
staining intensity. 
 
Immunofluorescence 
 
Cells were grown on coverslips and fixed for 6 min in 
4% paraformaldehyde at room temperature. After 
washing with PBS, the cells were permeabilized for 6 
min using 0.1% Triton X-100, blocked in 1% BSA for  
1 h, and incubated for 1 h at room temperature  
with primary monoclonal antibodies: anti-Nrf2, sc-
365949; anti-SQSTM1/p62, sc-28359 (Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA), and anti-
myogenin, ab124800 (Abcam, Cambridge, MA, USA) 
diluted in blocking buffer. After washing the cells 3 
times with PBS and 2 times with blocking buffer, 
fluorescently-labeled secondary antibodies diluted in 
blocking buffer were applied for 30-45 min at room 
temperature in the dark. The cells were then washed 
with PBS, and the coverslips mounted on glass slides 
for microscopy. 
 
Plasmid DNA construction and luciferase reporter 
assays 
 
Full-length mouse Nrf2 c-DNA was inserted into 
pSG5.HA and pEGFP vectors via the XhoI-KpnI 
restriction site. Mouse wild-type (WT) SQSTM1/p62 
and myogenin promoter fragments were inserted into a 
pGL3-LUC vector at the BamHI/XhoI site. The 
Nrf2(ARE)-LUC reporter was purchased from Signosis 
Inc. (Cat# LR-2106, Santa Clara, CA, USA). In turn, 
two reporter constructs containing regions located -2550 
 
www.aging-us.com 21464 AGING 
to +63 base pairs (bp) in the mouse p62 promoter and -
2715 to +52 bp in the mouse myogenin promoter were 
generated. Mutant ARE in the SQSTM1/p62 and 
myogenin promoters were constructed through PCR-
based site-directed mutagenesis (Figure 7A and 7B, 
respectively).  
 
Luciferase activity was monitored in C2C12 cells 
transfected over 24 h with the reporter plasmids (0.25 
μg) using a Dual-Luciferase Reporter Assay Kit 
(Promega, MI, USA) according to the manufacturer’s 
instructions [44]. Luciferase activities in cell extracts 
are presented as relative light units (RLU) and 
expressed as the mean ± standard deviation of results 
from three independent cell cultures. 
 
Animal experiments 
 
Eight-week-old male C57B6 mice (25-30 g) were 
housed in a light- and temperature-controlled room with 
ad libitum access to deionized drinking water and 
standard chow. After a 1-week acclimatization period, 
the animals were randomly assigned to one of two 
groups (n = 12 mice/group) and subjected to either a 
sham operation or two-stage 5/6 nephrectomy (5/6 Nx; 
to model CKD) under ketamine/xylazine anesthesia 
(90/9 mg/kg, i.p.). During the first stage of 
nephrectomy, approximately two thirds of the left 
kidney were removed after ligation of the upper and 
lower poles. One week later, the entire right kidney was 
removed after ligation of the vascular pedicle. The sham 
operation involved a flank incision and gentle 
manipulation of the kidney, without altering its 
structure, on the same day that mice in the CKD group 
were subjected to the first stage of nephrectomy. Both 
sham-operated and 5/6 Nx mice were then assigned to 
two subgroups (n = 6 mice/group) and fed, respectively, 
a high-Pi (2% Pi) and a normal-Pi (0.6% Pi) diet. After 
5 months on the respective diets, mouse hind limb grip 
strengths were measured using a MK-380 grip strength 
meter (Muromachi Kikai Co., Ltd., Tokyo, Japan). 
Serum samples were collected for analysis of BUN, Cr, 
Ca
2+
, Pi, iPTH, and FGF23. GA muscles from the 
sacrificed mice were weighed and processed for 
immunoblot analysis of Nrf2, p62, and myogenin 
expression. The Animal Ethics Board of the National 
Defense Medical Center (Taipei, Taiwan) approved all 
animal experimental procedures. 
 
Statistical analyses 
 
All values are given as means ± SEM unless stated 
otherwise. Unpaired Student’s t-tests were used for two-
group comparisons, and one-way analysis of variance 
was used for comparisons among multiple groups. All 
analyses were performed using GraphPad Prism version 
5 software (GraphPad Software Inc., CA, USA). P < 
0.05 was considered significant. 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Tables 
 
 
Supplementary Table 1. List of the antibodies used for immunoblot analyses.  
Santa Cruz:   
MYH  sc-376157  1:2000  
Cyclin D1  sc-718  1:1000  
p21  sc-397  1:1000  
beta-actin  sc-47778  1:10000  
Myo D  sc-304  1:1000  
Nrf-2  sc-365949  1:1000  
p62  sc-28359  1:1000  
Abcam:    
Myogenin  ab124800  1:2000  
p-Nrf-2 (S40)  ab76026  1:1000  
MuRF  ab77577  1:1000  
Atrogin-1  ab74023  1:1000  
Cell signaling:   
Troponin I  #4002  1:1000  
p-p62 (S349)  #95697  1:1000  
p-p62 (Thr269/Ser272)  #13121  1:1000  
Atg7  #8558  1:1000  
Beclin-1  #3495  1:1000  
LC3B  #2775  1:1000  
p-p70 S6K (Tyr389)  #9205  1:1000  
p70 S6K  #2708  1:1000  
p-mTOR  #2971  1:1000  
mTOR  #2972  1:1000  
MLC2v  #8505  1:1000  
Proteintech:   
Keap1  60027-I-Ig  1:1000  
 
Supplementary Table 2. PCR primers used in this study. 
Gene name  Primer (5’→3’) 
myogenin  Forward: 5’-CTACCTTCCTGTCCACCTTC-3’ 
 Reverse: 5’-CTCCAGTGCATTGCCCCACT-3’ 
MYH  Forward: 5’-GCCTCATCCACACCAAGAAGA-3’ 
 Reverse: 5’-TCCACCAGATCCTGCAATCTC-3’ 
Troponin I  Forward: 5’-GCAAAAGTCACCAAGAACATC-3’ 
 Reverse: 5’-GCGCCAGTCTCCCACCTCCCGG-3’ 
p21  Forward: 5’-GCTGTCTCCAGGAGGCCCG-3’ 
 Reverse: 5’-GCTGGTCTGCCTCCGTTTTCG-3’ 
cyclin D1  Forward: 5’-ATGGAACACCAGCTCCTGTG-3’ 
 Reverse: 5’-CTTAGAGGCCACGAACATGC-3’ 
Myo D1  Forward: 5’-CAGCGGGCACCACCAG-3’ 
 Reverse: 5’- ATGCTGGACAGGCAGTC-3’ 
GAPDH  Forward: 5’-CTTCATTGACCTCAACTAC-3’ 
 Reverse: 5’-GCCATCCACAGTCTTCTG-3’ 
 
  
